Tapestry, Inc. vs Zoetis Inc — how do they compare? Tapestry, Inc. trades at $154.3 (market cap $32.44B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Tapestry, Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| TPR | ZTS | |
|---|---|---|
Market Cap | $32.44B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $164.78 | $156.76 |
52-Week Low | $95.69 | $71.91 |
Enterprise Value | $35.29B | $38.70B |
Dividend Yield | 1% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
TPR trades at $154.39, down 6.31% over 24 hours, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent earnings beats and a 75.61% buy rating highlight positive momentum. The company maintains robust gross margins of 76.18% and ROE of 55.74%, though elevated P/E of 48.95 signals premium valuation. Upcoming Q4 2026 earnings on August 13, 2026, and a $0.40 dividend payment on June 22, 2026, are key near-term catalysts.
Outlook remains favorable with a consensus price target of $190.33, implying 23% upside, driven by earnings growth and AI integration initiatives. Risks include high debt levels, competitive pressures, and sensitivity to consumer spending. Investors should weigh strong profitability against valuation concerns ahead of earnings.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →